BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients…
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy…
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…
- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each…
AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging…